The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies.
about
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesFactors associated with significant liver necroinflammation in chronic hepatitis B patients with cirrhosisNoninvasive assessment of liver fibrosis in patients with chronic hepatitis B.Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B.Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years.Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 proceduresLIVER BIOPSY: IMPORTANCE OF SPECIMEN SIZE IN THE DIAGNOSIS AND STAGING OF CHRONIC VIRAL HEPATITIS.Safety and performance of liver biopsies in liver transplant recipients.Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?Emergency right hepatectomy after laparoscopic tru-cut liver biopsy.Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis CAdequacy of percutaneous non-targeted liver biopsy under real-time ultrasound guidance when comparing the Biopince™ and Achieve™ biopsy needle.Complications and risk factors in 2731 diagnostic mini-laparoscopies in patients with liver disease.
P2860
Q27000080-5E195B9E-4A1E-4C67-BD24-9B6A4C150044Q30374334-E7B7C4FE-BFFF-4A53-8F8C-72356C34E4AAQ30430774-20433B43-2273-4F83-82E2-A115D9FBE3B0Q33389011-C2A8507F-7F26-41CA-977B-C4F12264386FQ34184642-478B4F9C-5A6A-4C5B-9461-3C53C9A22310Q34502316-A480DB7F-EFF0-4020-B87F-831E537264ADQ35818743-78152DC2-7C74-456C-8ADB-57AA878B6DE8Q35819904-0C91154B-9872-4A6A-9B47-AA2D87D2CB6AQ36692315-92CA747B-A597-486A-A566-8F7B4F62C3D3Q40214428-8088E18A-E4BB-4DD9-BD2B-41AB311AB254Q41608214-AA540E13-8C93-427C-BE11-4CA33744264EQ42148191-97DAC86F-C9A0-4FB4-84C6-2579FC1661B5Q42249972-C3106D3E-02FB-41A8-8F84-0CF56D623D91Q42318960-C51951A9-B0EC-443E-B79B-A3ABD3E2B63FQ47875192-855A39BE-370E-4689-A40E-92A330701607Q50958631-62EC9A14-7F69-4567-A019-A30D667A799F
P2860
The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The incidence and risks of liv ...... n evaluation of 3806 biopsies.
@en
The incidence and risks of liv ...... n evaluation of 3806 biopsies.
@nl
type
label
The incidence and risks of liv ...... n evaluation of 3806 biopsies.
@en
The incidence and risks of liv ...... n evaluation of 3806 biopsies.
@nl
prefLabel
The incidence and risks of liv ...... n evaluation of 3806 biopsies.
@en
The incidence and risks of liv ...... n evaluation of 3806 biopsies.
@nl
P2093
P356
P1433
P1476
The incidence and risks of liv ...... n evaluation of 3806 biopsies.
@en
P2093
Chia-Yen Dai
Liang-Yen Wang
Ming-Lung Yu
Ming-Yen Hsieh
Ming-Yuh Hsieh
Nai-Jen Hou
Shinn-Chern Chen
Wan-Long Chuang
Wen-Yu Chang
P2860
P304
P356
10.1136/GUT.2006.115410
P407
P50
P577
2007-05-01T00:00:00Z